Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder

Izelle Labuschagne, K. Luan Phan, Amanda Wood, Mike Angstadt, Phyllis Chua, Markus Heinrichs, Julie C. Stout, Pradeep J. Nathan

Research output: Contribution to journalArticle

Abstract

Patients with generalized social anxiety disorder (GSAD) exhibit heightened activation of the amygdala in response to social cues conveying threat (eg, fearful/angry faces). The neuropeptide oxytocin (OXT) decreases anxiety and stress, facilitates social encounters, and attenuates amygdala reactivity to threatening faces in healthy subjects. The goal of this study was to examine the effects of OXT on fear-related amygdala reactivity in GSAD and matched healthy control (CON) subjects. In a functional magnetic resonance imaging study utilizing a double-blind placebo-controlled within-subjects design, we measured amygdala activation to an emotional face matching task of fearful, angry, and happy faces following acute intranasal administration of OXT (24 IU or 40.32 μg) and placebo in 18 GSAD and 18 CON subjects. Both the CON and GSAD groups activated bilateral amygdala to all emotional faces during placebo, with the GSAD group exhibiting hyperactivity specifically to fearful faces in bilateral amygdala compared with the CON group. OXT had no effect on amygdala activity to emotional faces in the CON group, but attenuated the heightened amygdala reactivity to fearful faces in the GSAD group, such that the hyperactivity observed during the placebo session was no longer evident following OXT (ie, normalization). These findings suggest that OXT has a specific effect on fear-related amygdala activity, particularly when the amygdala is hyperactive, such as in GSAD, thereby providing a brain-based mechanism of the impact of OXT in modulating the exaggerated processing of social signals of threat in patients with pathological anxiety.
Original languageEnglish
Pages (from-to)2403-2413
Number of pages11
JournalEuropean Neuropsychopharmacology
Volume35
Issue number12
Early online date18 Aug 2010
DOIs
Publication statusPublished - Nov 2010

Fingerprint

Oxytocin
Amygdala
Fear
Placebos
Healthy Volunteers
Anxiety
Social Phobia
Intranasal Administration
Control Groups
Neuropeptides
Cues
Magnetic Resonance Imaging
Brain

Keywords

  • oxytocin
  • fear
  • emotion
  • amygdala
  • social anxiety disorder
  • functional magnetic resonance imaging
  • fMRI

Cite this

Labuschagne, I., Phan, K. L., Wood, A., Angstadt, M., Chua, P., Heinrichs, M., ... Nathan, P. J. (2010). Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder. European Neuropsychopharmacology, 35(12), 2403-2413. https://doi.org/10.1038/npp.2010.123
Labuschagne, Izelle ; Phan, K. Luan ; Wood, Amanda ; Angstadt, Mike ; Chua, Phyllis ; Heinrichs, Markus ; Stout, Julie C. ; Nathan, Pradeep J. / Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder. In: European Neuropsychopharmacology. 2010 ; Vol. 35, No. 12. pp. 2403-2413.
@article{10f29639b3a241c083dfa13db3eb05b5,
title = "Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder",
abstract = "Patients with generalized social anxiety disorder (GSAD) exhibit heightened activation of the amygdala in response to social cues conveying threat (eg, fearful/angry faces). The neuropeptide oxytocin (OXT) decreases anxiety and stress, facilitates social encounters, and attenuates amygdala reactivity to threatening faces in healthy subjects. The goal of this study was to examine the effects of OXT on fear-related amygdala reactivity in GSAD and matched healthy control (CON) subjects. In a functional magnetic resonance imaging study utilizing a double-blind placebo-controlled within-subjects design, we measured amygdala activation to an emotional face matching task of fearful, angry, and happy faces following acute intranasal administration of OXT (24 IU or 40.32 μg) and placebo in 18 GSAD and 18 CON subjects. Both the CON and GSAD groups activated bilateral amygdala to all emotional faces during placebo, with the GSAD group exhibiting hyperactivity specifically to fearful faces in bilateral amygdala compared with the CON group. OXT had no effect on amygdala activity to emotional faces in the CON group, but attenuated the heightened amygdala reactivity to fearful faces in the GSAD group, such that the hyperactivity observed during the placebo session was no longer evident following OXT (ie, normalization). These findings suggest that OXT has a specific effect on fear-related amygdala activity, particularly when the amygdala is hyperactive, such as in GSAD, thereby providing a brain-based mechanism of the impact of OXT in modulating the exaggerated processing of social signals of threat in patients with pathological anxiety.",
keywords = "oxytocin, fear, emotion, amygdala, social anxiety disorder, functional magnetic resonance imaging, fMRI",
author = "Izelle Labuschagne and Phan, {K. Luan} and Amanda Wood and Mike Angstadt and Phyllis Chua and Markus Heinrichs and Stout, {Julie C.} and Nathan, {Pradeep J.}",
year = "2010",
month = "11",
doi = "10.1038/npp.2010.123",
language = "English",
volume = "35",
pages = "2403--2413",
journal = "European Neuropsychopharmacology",
issn = "0924-977X",
publisher = "Nature Publishing Group",
number = "12",

}

Labuschagne, I, Phan, KL, Wood, A, Angstadt, M, Chua, P, Heinrichs, M, Stout, JC & Nathan, PJ 2010, 'Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder', European Neuropsychopharmacology, vol. 35, no. 12, pp. 2403-2413. https://doi.org/10.1038/npp.2010.123

Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder. / Labuschagne, Izelle; Phan, K. Luan; Wood, Amanda; Angstadt, Mike; Chua, Phyllis; Heinrichs, Markus; Stout, Julie C.; Nathan, Pradeep J.

In: European Neuropsychopharmacology, Vol. 35, No. 12, 11.2010, p. 2403-2413.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Oxytocin attenuates amygdala reactivity to fear in generalized social anxiety disorder

AU - Labuschagne, Izelle

AU - Phan, K. Luan

AU - Wood, Amanda

AU - Angstadt, Mike

AU - Chua, Phyllis

AU - Heinrichs, Markus

AU - Stout, Julie C.

AU - Nathan, Pradeep J.

PY - 2010/11

Y1 - 2010/11

N2 - Patients with generalized social anxiety disorder (GSAD) exhibit heightened activation of the amygdala in response to social cues conveying threat (eg, fearful/angry faces). The neuropeptide oxytocin (OXT) decreases anxiety and stress, facilitates social encounters, and attenuates amygdala reactivity to threatening faces in healthy subjects. The goal of this study was to examine the effects of OXT on fear-related amygdala reactivity in GSAD and matched healthy control (CON) subjects. In a functional magnetic resonance imaging study utilizing a double-blind placebo-controlled within-subjects design, we measured amygdala activation to an emotional face matching task of fearful, angry, and happy faces following acute intranasal administration of OXT (24 IU or 40.32 μg) and placebo in 18 GSAD and 18 CON subjects. Both the CON and GSAD groups activated bilateral amygdala to all emotional faces during placebo, with the GSAD group exhibiting hyperactivity specifically to fearful faces in bilateral amygdala compared with the CON group. OXT had no effect on amygdala activity to emotional faces in the CON group, but attenuated the heightened amygdala reactivity to fearful faces in the GSAD group, such that the hyperactivity observed during the placebo session was no longer evident following OXT (ie, normalization). These findings suggest that OXT has a specific effect on fear-related amygdala activity, particularly when the amygdala is hyperactive, such as in GSAD, thereby providing a brain-based mechanism of the impact of OXT in modulating the exaggerated processing of social signals of threat in patients with pathological anxiety.

AB - Patients with generalized social anxiety disorder (GSAD) exhibit heightened activation of the amygdala in response to social cues conveying threat (eg, fearful/angry faces). The neuropeptide oxytocin (OXT) decreases anxiety and stress, facilitates social encounters, and attenuates amygdala reactivity to threatening faces in healthy subjects. The goal of this study was to examine the effects of OXT on fear-related amygdala reactivity in GSAD and matched healthy control (CON) subjects. In a functional magnetic resonance imaging study utilizing a double-blind placebo-controlled within-subjects design, we measured amygdala activation to an emotional face matching task of fearful, angry, and happy faces following acute intranasal administration of OXT (24 IU or 40.32 μg) and placebo in 18 GSAD and 18 CON subjects. Both the CON and GSAD groups activated bilateral amygdala to all emotional faces during placebo, with the GSAD group exhibiting hyperactivity specifically to fearful faces in bilateral amygdala compared with the CON group. OXT had no effect on amygdala activity to emotional faces in the CON group, but attenuated the heightened amygdala reactivity to fearful faces in the GSAD group, such that the hyperactivity observed during the placebo session was no longer evident following OXT (ie, normalization). These findings suggest that OXT has a specific effect on fear-related amygdala activity, particularly when the amygdala is hyperactive, such as in GSAD, thereby providing a brain-based mechanism of the impact of OXT in modulating the exaggerated processing of social signals of threat in patients with pathological anxiety.

KW - oxytocin

KW - fear

KW - emotion

KW - amygdala

KW - social anxiety disorder

KW - functional magnetic resonance imaging

KW - fMRI

UR - http://www.nature.com/npp/journal/v35/n12/full/npp2010123a.html

U2 - 10.1038/npp.2010.123

DO - 10.1038/npp.2010.123

M3 - Article

VL - 35

SP - 2403

EP - 2413

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

SN - 0924-977X

IS - 12

ER -